Sanjay Mistry

Sanjay Mistry

Signal active

Director

Bio

Sanjay Mistry is the director at Rapport Therapeutics. Joined Quaker Partners in 2008. Dr. Mistry focused on selecting investments across the biopharma and diagnostics/tools sectors.

Prior to joining Quaker, he was an Assistant Director at Johnson & Johnson, where he held responsibilities in therapeutic area strategy planning and in the implementation and management of life science alliances for the Stem Cell Internal Ventures (SCIV) group.

Prior to his business development roles, he led stem cell translational development in the area of retinal degeneration within the SCIV. Dr. Mistry also worked at Morphogen Pharmaceuticals and completed postdoctoral fellowships at the Scripps Research Institute and at the University of Pittsburgh Medical School.

He holds a Ph.D. in Biochemical Pharmacology and an M.S. in Clinical Pharmacology from the University of Aberdeen and a B.Sc. in Applied Biology from Nottingham.

Location

San Diego, California, United States, North America

Social

Primary Organization

Rapport Therapeutics

Rapport Therapeutics

Founded

2022

Employees

11-50

Industry

Biotechnology, Life Science, Health Care, Medical, Precision Medicine

Jobs history

2

Rapport Therapeutics

Director

2022 - Current

Rapport Therapeutics

Board Member

Invalid date - Current

Board and Advisor Roles

0

N/A

Invest in regions

Profile Resume

Sanjay Mistry is the Director at Rapport Therapeutics, based in United States, North America. With a background in Biotechnology, Sanjay Mistry has a rich history of leadership and innovation. Sanjay Mistry studied BS Applied Biology @ University of Nottingham. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.

Recommendation from your interest

N/A

Investment portfolio

N/A

Number of investment

1

Number of exits

0

Personal investment

0

There is no personal investment available on this profile

Partner investment

2

Annouced DateOrganization NameFunding RoundInvestor NameMoney Raised
Mar 07, 2023
Rapport Therapeutics Rapport Therapeutics
Series A - Rapport Therapeutics
-100.0M
Aug 23, 2023
Rapport Therapeutics Rapport Therapeutics
Series B - Rapport Therapeutics
-150.0M

Exits

0

There is no exit available on this Profile

Invest in industries

Recent Activity

There is no recent news or activity for this profile.